Showing posts with label cancer biomarkers. Show all posts
Showing posts with label cancer biomarkers. Show all posts

Wednesday, September 14, 2011

Bold experimental treatment uses form of HIV to kill cancer

By Laura Shin | September 14, 2011, 5:41 AM PDT SMARTPLANET.COM

A bold experimental treatment has finally succeeded in accomplishing a goal that has eluded doctors for decades: it has trained the immune systems of cancer patients to search out and kill cancer cells.
The New York Timesreports, in a novel twist, that the doctors used a disabled form of HIV-1, the virus that causes AIDS, to deliver the new genes that would program the person’s own cells to attack the cancer.
The University of Pennsylvania doctors have tried the experimental treatment in three leukemia patients, two of whom went into full remission and one of whom has had a partial remission in which his leukemia remains in lessened form.
They published the results of their experiment with the first patient, William Ludwig, in the New England Journal of Medicine and Science Translational Medicine.

Results in first patient

The doctors — Dr. Carl June of the Abramson Cancer Center at the University of Pennsylvaniaand colleagues Dr. David L. Porter, Bruce Levine and Michael Kalos — began by removing a billion of Ludwig’s T-cells, which are white blood cells that fight tumors and viruses.
They then altered the genes of the T-cells so they would attack cancer, and returned those modified T-cells to his bloodstream.
For the first ten days, nothing happened. But then, according to the Times, “hell broke loose in his hospital room. He began shaking with chills. His temperature shot up. His blood pressure shot down. He became so ill that doctors moved him into intensive care and warned that he might die. His family gathered at the hospital, fearing the worst.”
But within a few weeks, the fevers subsided, leaving no trace of cancer in their wake. No leukemic cells were found in his blood or bone marrow, and doctors calculated that two pounds of cancer cells had been killed off.
A year later, Ludwig’s remission remains complete. He has gained 40 pounds, plays golf, does yard work and travels with his wife in an R.V. Before the study, he sometimes could barely get out of bed and frequently suffered bouts of pneumonia. “I have my life back,” he told the Times.

How the therapy works and uses the HIV virus

In order for T-cells to kill cancer cells, they must be able to do several things: recognize the cancer, fight it, multiply and continue living inside the patient. Previous attempts to make T-cells do all these things failed, resulting in cells that, for instance, could only temporarily fight tumors.
However, this experiment enabled the modified T-cells to multiply to 1,000 to 10,000 times the amount originally altered by the researchers. In those numbers, they wiped out the cancer and then gradually diminished, but there remains a population of memory cells that could proliferate if needed.
The particular type of leukemia treated in this case was chronic lymphocytic leukemia, which afflicts B-cells. The doctors gave the T-cells genes that would make them find and attack a protein found on all B-cells, whether they are healthy or leukemic.
But it is not easy to decide which genes to insert and how to insert them. Viruses are natural delivery vehicles because they specialize in invading the genes of cells. In this case, because doctors wanted to modify T-cells, the AIDS virus was chosen because it naturally invades T-cells.
While other researchers have used HIV-1 to insert DNA into cells in gene therapy for other diseases, Dr. June and his colleagues were the first to use it in gene therapy for cancer patients.
This particular form of HIV-1 was no longer dangerous because other researchers had added DNA from humans, mice and cows and from a virus that infects woodchucks and another that infects cows.
But this type of therapy is not without risks. In other experiments, engineered T-cells have attacked the healthy tissue of patients. And, having been done in only three patients, the new T-cell treatment is not yet proven to work and has not yet been mass-produced by the drug industry.
Dr. June said his team’s next focus is using T-cells to attack solid tumors, such as mesothelioma and ovarian and pancreatic cancer.
Watch them discussing their method in this video:




photo: the engineered T-cells with magnetic beads attached to them; the beads are removed prior to infusion into the patient. (University of Pennsylvania)

Monday, February 28, 2011

Dual-energy CT images cancer biomarkers

by : medicalphysicsweb 


Spectral CT, an emerging technique that images using X-rays of more than one energy, can differentiate multiple tissue types or contrast agents within the body. At the SPIE Medical Imaging conference, held last week in Lake Buena Vista, FL, Cristian Badea from Duke University Medical Center (Durham, NC) described the application of dual-energy microCT to simultaneously image iodine and gold probes in vivo.



Badea and colleagues examined two nanoprobes: liposomal iodine (Lip-I) and gold nanoparticles. The Lip-I probes comprised an aqueous iohexol core surrounded by a lipid bilayer and PEGylated to ensure retention in the blood. The gold probe was AuroVist, a commercial contrast agent comprising 15 nm nanoparticles. Both probes are cleared from the body via the liver and spleen.
As gold and iodine exhibit different attenuation coefficient profiles, with K-edges at different energies (81 and 33 keV, respectively), it should be possible to distinguish the two by comparing X-ray images at different energies. To determine the optimal imaging parameters, Badea's team built a dual-energy microCT system, containing two X-ray tubes and two detectors.
First, the researchers used the Spektr computational tool to model the microCT system's performance, using a phantom containing varying volumes of the two probes and imaging at voltages from 40 to 150 kVp. Plots of contrast versus voltage revealed that at 40 kVp, signals from regions containing gold nanoparticles were brightest, while iodine provided maximum enhancement at around 70 and 80 kVp.
They then performed phantom experiments to measure CT enhancement for the probes across the same voltage range. The measured images agreed with the simulated results, showing maximum CT enhancement at 40 kVp for the gold nanoparticles and 80 kVp for the Lip-I. On a mass-concentration basis, the relative average enhancement of gold to iodine was 2.75 at 40 kVp and 1.58 at 80 kVp.
The team also used the phantom images to determine the limits of detectability of the two probes. Calculating the contrast-to-noise ratio at different concentrations revealed a limit of 20 mg/ml for the Lip-I probes and 10 mg/ml for gold nanoparticles. The use of averaging to reduce the noise improved these values to 15 and 6 mg/ml for Lip-I, and gold respectively.

In vivo assessment

The researchers also used the dual-energy microCT system to perform in vivo imaging of mice with colon cancer tumours. Mice were injected with 0.1 ml gold nanoparticles (with a gold concentration of 200 mg/ml) and then imaged 72 hours later at 40 and 80 kVp. The mice were then injected with 0.4 ml of the Lip-I probe and rescanned.
Maximum intensity projection images showed that Lip-I probes visualized the blood vessels, while gold probes revealed the liver, spleen and some enhancement into the tumour due to extravasation of the nanoparticles.
"This dual-energy microCT provides a way to image 3D vasculature and permeability in tumours," concluded Badea, associate professor of radiology at Duke's Center for In Vivo Microscopy. "These are both important biomarkers in cancer studies."